Unlock stock picks and a broker-level newsfeed that powers Wall Street.

HKSE - Delayed Quote HKD

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK)

Compare
13.980
+0.160
+(1.16%)
At close: 4:08:07 PM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
41,067,195.863
41,067,195.863
41,399,539.588
43,951,546.895
39,011,184.282
Cost of Revenue
21,365,573.972
21,365,573.972
21,595,308.757
23,169,690.420
20,229,784.681
Gross Profit
19,701,621.890
19,701,621.890
19,804,230.831
20,781,856.476
18,781,399.601
Operating Expense
16,498,479.846
16,498,479.846
18,240,906.771
17,145,016.826
16,071,626.609
Operating Income
3,203,142.045
3,203,142.045
1,563,324.061
3,636,839.649
2,709,772.992
Net Non Operating Interest Income Expense
-1,110,518.015
-1,110,518.015
-997,350.084
-709,762.380
-618,688.816
Pretax Income
4,169,281.680
4,169,281.680
3,264,567.879
4,574,381.585
6,042,670.590
Tax Provision
656,841.295
656,841.295
369,504.452
626,917.465
1,066,401.220
Net Income Common Stockholders
2,769,886.631
2,769,886.631
2,386,265.814
3,730,804.583
4,728,710.527
Basic EPS
1.04
--
0.89
1.43
1.85
Diluted EPS
1.04
--
0.89
1.43
1.85
Basic Average Shares
2,663,352.530
--
2,681,197.544
2,608,954.254
2,556,059.745
Diluted Average Shares
2,663,352.530
--
2,681,197.544
2,608,954.254
2,556,059.745
Total Operating Income as Reported
4,245,103.909
4,245,103.909
3,307,507.905
4,656,656.381
6,302,568.209
Total Expenses
37,864,053.818
37,864,053.818
39,836,215.527
40,314,707.246
36,301,411.290
Net Income from Continuing & Discontinued Operation
2,769,886.631
2,769,886.631
2,386,265.814
3,730,804.583
4,728,710.527
Normalized Income
2,729,556.132
2,729,556.132
3,072,203.211
6,069,937.752
5,195,654.896
Interest Income
373,210.305
373,210.305
363,645.386
282,634.639
233,727.097
Interest Expense
1,431,914.682
1,431,914.682
1,324,830.526
963,806.918
822,534.029
Net Interest Income
-1,110,518.015
-1,110,518.015
-997,350.084
-709,762.380
-618,688.816
EBIT
5,601,196.362
5,601,196.362
4,589,398.404
5,538,188.503
6,865,204.619
EBITDA
8,602,739.349
8,602,739.349
7,554,583.034
7,874,099.748
8,699,592.892
Reconciled Cost of Revenue
21,365,573.972
21,365,573.972
21,595,308.757
23,169,690.420
20,229,784.681
Reconciled Depreciation
3,001,542.988
3,001,542.988
2,965,184.630
2,335,911.245
1,834,388.272
Net Income from Continuing Operation Net Minority Interest
2,769,886.631
2,769,886.631
2,386,265.814
3,730,804.583
4,728,710.527
Total Unusual Items Excluding Goodwill
47,872.474
47,872.474
-773,485.365
-2,710,623.166
-567,009.298
Total Unusual Items
47,872.474
47,872.474
-773,485.365
-2,710,623.166
-567,009.298
Normalized EBITDA
8,554,866.875
8,554,866.875
8,328,068.400
10,584,722.914
9,266,602.190
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
7,541.975
7,541.975
-87,547.969
-371,489.997
-100,064.930
12/31/2021 - 10/30/2012

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

2161.HK JBM (Healthcare) Limited
2.080
-0.48%
 
1558.HK HEC CJ PHARM
11.900
+1.02%
 
6185.HK CanSino Biologics Inc.
29.500
+2.97%
 
INM InMed Pharmaceuticals Inc.
2.7162
+3.28%
 
HCM HUTCHMED (China) Limited
13.76
+0.15%
 
UTHR United Therapeutics Corporation
284.73
-0.16%
 
HLN Haleon plc
10.22
+0.59%
 
4105.TWO TTY Biopharm Company Limited
72.60
-0.82%
 
3705.TW YungShin Global Holding Corporation
66.10
-0.90%
 
TEVA Teva Pharmaceutical Industries Limited
13.65
+1.64%